New York Firm Raises $48 Million To Develop New Cancer Immunotherapies

Retrieved on: 2018-02-26 20:22:30

Tags for this article:

Health

Immune system

Endoplasmic reticulum

Laurie Glimcher

Click the tags to see associated articles and topics

New York Firm Raises $48 Million To Develop New Cancer Immunotherapies. View article details on HISWAI:

Excerpt

<div>Investors include Versant Ventures, which founded the company, and by <b>Polaris</b> <b>Partners</b> and the affiliated LS Polaris Innovation Fund as well as AbbVie Ventures, Taiho Pharmaceutical Co., Ltd., Yonghua Capital, Alexandria Venture Investments and the New York Ventures, the investment arm of ...</div>

Article found on:

View Original Article